Why Genenta Science S.p.A.’s (GNTA) Stock Is Down 5.45%
As of Wednesday, June 03, Genenta Science S.p.A.’s GNTA share price has dipped by 5.45%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Commentary & Analysis
Why Genenta Science S.p.A.’s (GNTA) Stock Is Down 43.23%
As of Monday, October 27, Genenta Science S.p.A.’s GNTA share price has dipped by 43.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Genenta Science S.p.A.’s (GNTA) Stock Is Up 98.79%
As of Friday, October 24, Genenta Science S.p.A.’s GNTA share price has surged by 98.79%, which has investors questioning if this is right time to sell.Tudor Pop
Why Genenta Science S.p.A.’s (GNTA) Stock Is Up 7.59%
As of Wednesday, October 15, Genenta Science S.p.A.’s GNTA share price has surged by 7.59%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genenta Science S.p.A.’s (GNTA) Stock Is Down 10.66%
As of Tuesday, October 14, Genenta Science S.p.A.’s GNTA share price has dipped by 10.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $29.7 | $292.6 | 12% |
|
| Shares Out (Mil) | 24.2 | 54.4 | 33% |
|
| Institutional Ownership | 16.9% | 93.2% | 8% |
|
| Float (Mil) | 13.9 | 40.2 | 23% |
|
| Beta | 0.90 | 0.94 | 54% |
|
| Avg Daily Volume (000s) | 35 | 544 | 24% |
|
| Price Change (52-week) |
(64.4%) | 59.7% | 10% |
|
| Growth | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (2.5%) | (10.1%) | 37% |
|
| EPS (5yr) | 3.7% | 16.0% | 36 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.6% | (15.6%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 31% |
|
| EPS (TTM) | ($0.389) | ($1.400) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $25 | $164 | 13% |
|
| Valuation | GNTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.16 | 2.83 | 27% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GNTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (29.0%) | (47.5%) | 17% |
|
| ROE | (39.7%) | (55.0%) | 17% |
|
| Liabilities to Assets | 31.5% | 29.6% | 23% |
|
| F-Score | 2 | 3 | 7% |
|
Genenta Science S.p.A. did not pass any screens on 8/21/2026.
